博安生物BA1106聯合BA1104 II期臨床試驗申請獲CDE受理 X
26/04/2026 20:44
<匯港通訊>    博安生物(06955)宣佈,公司自主開發的創新抗體BA1106(抗CD25單抗)聯合其自有的PD-1抑制劑BA1104(納武利尤單抗)用於非小細胞肺癌(NSCLC)一線和二線治療的II期臨床試驗申請,已於近日獲得國家藥品監督管理局藥品審評中心(CDE)受理。 (WL)



Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.